While many articles such as this discuss the flaws
Post# of 148292
(Total Views: 602)
Posted On: 10/09/2020 5:27:03 PM
While many articles such as this discuss the flaws in big pharma’s attempts at a treatment, a small biotech, CytoDyn, has an investigational drug, leronlimab, that is showing fantastic efficacy. This drug is now in FDA Phase 2 trails for mild to moderate infections and Phase 2b/3 for serious illness. It appears to be batting 1000 against the cytokine storm and is restoring patient’s immune response to fight the infection. Several patients have been discharged within only a few days of treatment.
How can we get this on the front page ?
How can we get this on the front page ?
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼